Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 5/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.57 |
| ▸ | F10 | P00742 | 2/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 6/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | C1S | P09871 | 1/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.48 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.46 |
| ▸ | MASP2 | O00187 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366568 | 0.81 | PLA2G10 (0.59) | — | |
| SCHEMBL1445806 | 0.80 | PRSS1 (0.53) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL2717268 | 0.80 | PRSS1 (0.70) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL18324125 | 0.79 | PRSS1 (0.57) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL11139354 | 0.76 | CYP3A4 (0.42) | — | |
| SCHEMBL1445939 | 0.76 | PRSS1 (0.48) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL1587085 | 0.76 | PRSS1 (0.64) | PRSS1PRSS3PRSS2F10LOXL2 | |
| SCHEMBL11788529 | 0.75 | CYP2C9 (0.42) | PRSS1F2ST14 | |
| SCHEMBL1446332 | 0.75 | KMT2A (0.39) | PRSS1PRSS3PRSS2F2PLG | |
| SCHEMBL7719735 | 0.75 | PRSS1 (0.52) | PRSS1PRSS3PRSS2F10LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366786-A2 | Cytokine receptor modulators and uses thereof | VALORISATION HSJ, Société en Commandite (CA) | 2011-09-21 | — | — | EP | claimed |
| EP-2288621-A2 | IL-23 RECEPTOR ANTAGONISTS AND USES THEREOF | Valorisation HSJ, Societe en Commandite (CA) | 2011-03-02 | — | — | EP | claimed |
| EP-1885855-A4 | CYTOKINE RECEPTOR MODULATORS AND USES THEREOF | VALORISATION HSJ SOC EN COMMAN (CA) | 2009-03-04 | — | — | EP | claimed |
| US-20090048161-A1 | Cytokine receptor modulators and uses thereof | VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) | 2009-02-19 | — | — | US | claimed |
| WO-2009007849-A2 | IL-23 RECEPTOR ANTAGONISTS AND USES THEREOF | VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) | 2009-01-15 | — | — | WO | claimed |
| EP-1751175-A4 | INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT | VALORISATION RECH SOC EN COMMA (CA) | 2008-12-17 | — | — | EP | claimed |
| EP-1885855-A2 | CYTOKINE RECEPTOR MODULATORS AND USES THEREOF | VALORISATION HSJ, Société en Commandite (CA) | 2008-02-13 | — | — | EP | claimed |
| EP-1751175-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT | Valorisation-Recherche, Société en Commandite (CA) | 2007-02-14 | — | — | EP | claimed |
| WO-2007004060-A2 | CYTOKINE RECEPTOR MODULATORS AND USES THEREOF | VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) | 2007-01-11 | — | — | WO | claimed |
| US-20060094663-A1 | Interleukin-1 receptor antagonists, compositions, and methods of treatment | VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) | 2006-05-04 | — | — | US | claimed |
| WO-2005105830-A1 | INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT | VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (CA) | 2005-11-10 | — | — | WO | claimed |
| EP-0384362-B1 | Glycinderivatives | HOFFMANN LA ROCHE (CH) | 1999-12-15 | — | — | EP | claimed |
| US-5663297-A | OLIGOPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1997-09-02 | — | — | US | claimed |
| EP-0384362-A2 | Glycinderivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-29 | — | — | EP | claimed |
| US-8802818-B2 | Prostaglandin-F2 alpha receptor modulators and uses thereof | LUBELL WILLIAM D (CA) | 2014-08-12 | — | — | US | disclosed |
| US-8618054-B2 | Interleukin-1 receptor antagonists, compositions, and methods of treatment | Valorisation-Rechereche Société en Commandite (CA) | 2013-12-31 | — | — | US | disclosed |
| US-20120309690-A1 | PROSTAGLANDIN-F2 ALPHA RECEPTOR MODULATORS AND USES THEREOF | LUBELL WILLIAM D (CA) | 2012-12-06 | — | — | US | disclosed |
| CN-1202893-A | Novel isoxazoline and isoxazole fibrinogen receptor antagonists | DU PONT MERCK PHARMA (US) | 1998-12-23 | — | — | CN | disclosed |
| US-5663297-A | OLIGOPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0384362-A2 | Glycinderivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309690-A1 | PROSTAGLANDIN-F2 ALPHA RECEPTOR MODULATORS AND USES THEREOF | PTGFR, PTGER1, PTGER2 | PRSS1 1539/4885PRSS3 2355/4885PRSS2 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.